[go: up one dir, main page]

CO6362025A2 - Anticuerpos contra la proteína tweak humana y usos de los mismos - Google Patents

Anticuerpos contra la proteína tweak humana y usos de los mismos

Info

Publication number
CO6362025A2
CO6362025A2 CO11108197A CO11108197A CO6362025A2 CO 6362025 A2 CO6362025 A2 CO 6362025A2 CO 11108197 A CO11108197 A CO 11108197A CO 11108197 A CO11108197 A CO 11108197A CO 6362025 A2 CO6362025 A2 CO 6362025A2
Authority
CO
Colombia
Prior art keywords
same
antibodies against
tweak protein
human tweak
protein
Prior art date
Application number
CO11108197A
Other languages
English (en)
Inventor
Monika Baehner
Hendrik Knoetgen
Jens Niewoehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CO6362025A2 publication Critical patent/CO6362025A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Anticuerpo que se une a la proteína TWEAK, caracterizado por una unión a la proteína TWEAK que se caracteriza porque comprende como dominio variable de cadena pesada una CDR3H seleccionada de entre el grupo que consiste de las secuencias SEC ID n° 8, 16 ó 24.F.
CO11108197A 2009-04-02 2011-08-24 Anticuerpos contra la proteína tweak humana y usos de los mismos CO6362025A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09004905 2009-04-02

Publications (1)

Publication Number Publication Date
CO6362025A2 true CO6362025A2 (es) 2012-01-20

Family

ID=40673340

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11108197A CO6362025A2 (es) 2009-04-02 2011-08-24 Anticuerpos contra la proteína tweak humana y usos de los mismos

Country Status (23)

Country Link
US (3) US8093006B2 (es)
EP (2) EP2414398A2 (es)
JP (1) JP5596777B2 (es)
KR (1) KR101344611B1 (es)
CN (1) CN102369219A (es)
AR (1) AR076020A1 (es)
AU (1) AU2010233997A1 (es)
BR (1) BRPI1014867A2 (es)
CA (1) CA2756245A1 (es)
CL (1) CL2011002452A1 (es)
CO (1) CO6362025A2 (es)
CR (1) CR20110462A (es)
EC (1) ECSP11011362A (es)
IL (1) IL214355A0 (es)
MA (1) MA33097B1 (es)
MX (1) MX2011010117A (es)
NZ (1) NZ594347A (es)
PE (1) PE20120577A1 (es)
RU (1) RU2011143903A (es)
SG (2) SG175005A1 (es)
TW (1) TWI423815B (es)
UA (1) UA105520C2 (es)
WO (1) WO2010115555A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9526846B2 (en) 2009-08-19 2016-12-27 Safety Syringes, Inc. Patient-contact activated needle stick safety device
WO2011097500A2 (en) 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
PH12013500506A1 (en) 2010-10-05 2017-08-23 Hoffmann La Roche Antibodies against human tweak and uses thereof
WO2012122513A2 (en) 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
CA2868404A1 (en) 2012-04-05 2013-10-10 F. Hoffmann-La Roche Ag Bispecific antibodies against human tweak and human il17 and uses thereof
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN103399151A (zh) * 2013-06-24 2013-11-20 上海交通大学医学院附属瑞金医院 Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用
SG11202104463YA (en) * 2018-10-31 2021-05-28 Astellas Pharma Inc Anti-human fn14 antibody
WO2025005938A1 (en) * 2023-06-26 2025-01-02 Memorial Sloan-Kettering Cancer Center Antibodies and antigen binding fragments thereof binding to chimeric receptors and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
CN1308451C (zh) 1996-08-07 2007-04-04 拜奥根Idec马萨诸塞公司 肿瘤坏死因子相关配基
JP2001513626A (ja) 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
AU736549B2 (en) 1997-05-21 2001-08-02 Merck Patent Gesellschaft Mit Beschrankter Haftung Method for the production of non-immunogenic proteins
WO1999019490A1 (en) 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
CA2358684C (en) * 1999-01-15 2013-07-16 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
AU2937300A (en) 1999-03-04 2000-09-21 Vision Sciences, Inc. Image sensor's unit cell with individually controllable electronic shutter circuit
GB9922069D0 (en) 1999-09-17 1999-11-17 Technolog Ltd Water distribution pressure control method and apparatus
WO2001030374A1 (en) 1999-10-22 2001-05-03 The University Of Pittsburgh Stem cell engraftment-enhancing cellular proteins and their uses
WO2001030429A1 (en) 1999-10-22 2001-05-03 Scimed Life Systems, Inc. Guided injection device
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
WO2001085193A2 (en) 2000-05-08 2001-11-15 Biogen, Inc. Method for promoting neovascularization using a tweak agonist and an angiogenic factor
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
EP2301578A3 (en) 2002-04-09 2012-08-08 Biogen Idec MA Inc. Methods for treating TWEAK-related conditions
CA2587018A1 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
WO2006096487A2 (en) 2005-03-07 2006-09-14 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
AU2006244014B2 (en) 2005-05-10 2011-03-17 Biogen Ma Inc. Treating and evaluating inflammatory disorders
WO2006130429A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
MEP35408A (en) * 2005-05-27 2011-02-10 Biogen Idec Inc Tweak binding antibodies
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
CR20110462A (es) 2011-09-21
JP2012521771A (ja) 2012-09-20
US20120083015A1 (en) 2012-04-05
CL2011002452A1 (es) 2012-03-23
UA105520C2 (uk) 2014-05-26
NZ594347A (en) 2012-09-28
KR101344611B1 (ko) 2013-12-30
TW201039847A (en) 2010-11-16
AU2010233997A1 (en) 2011-08-18
ECSP11011362A (es) 2011-10-31
RU2011143903A (ru) 2013-05-10
MX2011010117A (es) 2011-10-14
EP2597104A1 (en) 2013-05-29
PE20120577A1 (es) 2012-05-23
IL214355A0 (en) 2011-09-27
MA33097B1 (fr) 2012-03-01
CA2756245A1 (en) 2010-10-14
KR20110122868A (ko) 2011-11-11
WO2010115555A3 (en) 2011-01-06
JP5596777B2 (ja) 2014-09-24
AR076020A1 (es) 2011-05-11
US8093006B2 (en) 2012-01-10
BRPI1014867A2 (pt) 2016-04-12
US8883976B2 (en) 2014-11-11
TWI423815B (zh) 2014-01-21
SG10201404107SA (en) 2014-10-30
SG175005A1 (en) 2011-11-28
US20120207750A1 (en) 2012-08-16
US20100255008A1 (en) 2010-10-07
US8852887B2 (en) 2014-10-07
CN102369219A (zh) 2012-03-07
WO2010115555A2 (en) 2010-10-14
EP2414398A2 (en) 2012-02-08

Similar Documents

Publication Publication Date Title
CO6362025A2 (es) Anticuerpos contra la proteína tweak humana y usos de los mismos
AR074756A1 (es) Anticuerpos contra la angiopoyetina-2 humana
UY31862A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CR20110631A (es) Inmunoglobulina con dominio variable dual y usos de la misma
UY31861A (es) Inmunoglobulina con dominio variable dual y usos de la misma
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
PE20121616A1 (es) Anticuerpos anti-her3
AR075604A1 (es) Anticuerpos contra un ligando que induce proliferacion (april)
CR20120266A (es) Inmunoglobinas con dominio variable dual y usos de las mismas
ES2667568T3 (es) Anticuerpo anti-B7-H3
CR20130351A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (diviisional 9819)
CO6680687A2 (es) Inmunoglobinas con dominio variable dual capaces de unirse a il 1 beta e il-17, composiciones farmaceúticas y conjugados de proteína de unión de las mismas
CO6331296A2 (es) Inmunoglobulinas de dominio variable dual y usos de las mismas
EP2331136A4 (en) FRIZZLED-BINDING SUBSTANCES AND ITS USES
EA201370081A1 (ru) Антитела к cd48 и их применение
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
EA201391507A1 (ru) АНТИТЕЛА ПРОТИВ c-Kit И ИХ ПРИМЕНЕНИЕ
JO3118B1 (ar) تراكيب وطرق لبروتين c5 المتمم يستهدف الأجسام المضادة
UA112416C2 (uk) Антитіло до fap і способи його застосування
EA201690310A1 (ru) Антитела, связывающие cd27 человека, и их применение
AR077756A1 (es) Anticuerpos especificos para bacterias gram-positivas
CO6650372A2 (es) Proteínas de unión de dominio variable dual que se unen a tnfy tweak, y métopdos para hacer y usar dichas proteínas
PE20131411A1 (es) Anticuerpos contra la tweak humana y usos de los mismos
JO3437B1 (ar) أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها

Legal Events

Date Code Title Description
FG Application granted